Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,463,139
  • Shares Outstanding, K 50,413
  • Annual Sales, $ 385,690 K
  • Annual Income, $ -287,220 K
  • EBIT $ -206 M
  • EBITDA $ -195 M
  • 60-Month Beta 0.48
  • Price/Sales 19.32
  • Price/Cash Flow N/A
  • Price/Book 101.07

Options Overview Details

View History
  • Implied Volatility 44.01% (-1.81%)
  • Historical Volatility 31.62%
  • IV Percentile 51%
  • IV Rank 10.94%
  • IV High 117.66% on 12/23/24
  • IV Low 34.95% on 06/18/25
  • Expected Move (DTE 14) 11.05 (7.46%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 653
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 23,337
  • Open Int (30-Day) 22,170
  • Expected Range 136.99 to 159.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.73
  • Number of Estimates 10
  • High Estimate -0.51
  • Low Estimate -1.16
  • Prior Year -0.96
  • Growth Rate Est. (year over year) +23.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.01 +11.22%
on 11/06/25
152.94 -3.28%
on 11/25/25
+12.24 (+9.02%)
since 11/05/25
3-Month
112.90 +31.03%
on 09/16/25
152.94 -3.28%
on 11/25/25
+22.76 (+18.18%)
since 09/05/25
52-Week
75.56 +95.78%
on 12/30/24
152.94 -3.28%
on 11/25/25
+49.58 (+50.41%)
since 12/05/24

Most Recent Stories

More News
Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 149.99 (+1.32%)
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with...

AZN : 90.92 (+0.99%)
ATXI : 0.8000 (+5.19%)
AXSM : 149.99 (+1.32%)
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

FBIO : 2.83 (+2.91%)
ATXI : 0.8000 (+5.19%)
AXSM : 149.99 (+1.32%)
Biologics Market Surges Toward $680B as FDA Accelerates Approval Pathways

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges toward $679.56...

AVAI : 0.2950 (-0.03%)
VRTX : 460.95 (+0.78%)
WST : 280.13 (-0.58%)
RCKT : 3.43 (+0.29%)
AXSM : 149.99 (+1.32%)
Axsome: Q3 Earnings Snapshot

Axsome: Q3 Earnings Snapshot

AXSM : 149.99 (+1.32%)
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY ® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth ...

AXSM : 149.99 (+1.32%)
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

AXSM : 149.99 (+1.32%)
Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 149.99 (+1.32%)
UBS Remains a Buy on Axsome Therapeutics (AXSM)

UBS analyst Ashwani Verma maintained a Buy rating on Axsome Therapeutics today and set a price target of $163.00. The company’s shares closed yesterday at $129.58.Elevate Your Investing Strategy: Take...

AXSM : 149.99 (+1.32%)
Leerink Partners Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

In a report released on October 7, Marc Goodman from Leerink Partners maintained a Buy rating on Axsome Therapeutics. The company’s shares closed yesterday at $122.52.Elevate Your Investing Strategy:...

AXSM : 149.99 (+1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

See More

Key Turning Points

3rd Resistance Point 151.91
2nd Resistance Point 150.92
1st Resistance Point 149.48
Last Price 149.99
1st Support Level 147.05
2nd Support Level 146.06
3rd Support Level 144.62

See More

52-Week High 152.94
Last Price 149.99
Fibonacci 61.8% 123.38
Fibonacci 50% 114.25
Fibonacci 38.2% 105.12
52-Week Low 75.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar